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Clinical and radiographic spectrum of pathologically
confirmed tumefactive multiple sclerosis
C. F. Lucchinetti,1 R. H. Gavrilova,1 I. Metz,2 J. E. Parisi,3 B. W. Scheithauer,3 S. Weigand,4 K. Thomsen,4
J. Mandrekar,4 A. Altintas,5 B. J. Erickson,6 F. Ko«nig,2 C. Giannini,3 H. Lassmann,7 L. Linbo,1 S. J. Pittock1 and
W. Bru«ck2
1

Correspondence to: Claudia F. Lucchinetti, Mayo Clinic, Department of Neurology, College of Medicine, 200 First St SW,
Rochester, MN 55905, USA
Atypical imaging features of multiple sclerosis lesions include size `2 cm, mass effect, oedema and/or ring
enhancement.This constellation is often referred to as ‘tumefactive multiple sclerosis’. Previous series emphasize
their unifocal and clinically isolated nature, however, evolution of these lesions is not well defined. Biopsy may be
required for diagnosis.We describe clinical and radiographic features in 168 patients with biopsy confirmed CNS
inflammatory demyelinating disease (IDD). Lesions were analysed on pre- and post-biopsy magnetic resonance
imaging (MRI) for location, size, mass effect/oedema, enhancement, multifocality and fulfilment of Barkhof
criteria. Clinical data were correlated to MRI. Female to male ratio was 1.2 :1, median age at onset, 37 years,
duration between symptom onset and biopsy, 7.1 weeks and total disease duration, 3.9 years. Clinical course
prior to biopsy was a first neurological event in 61%, relapsing^remitting in 29% and progressive in 4%.
Presentations were typically polysymptomatic, with motor, cognitive and sensory symptoms predominating.
Aphasia, agnosia, seizures and visual field defects were observed. At follow-up, 70% developed definite multiple
sclerosis, and 14% had an isolated demyelinating syndrome. Median time to second attack was 4.8 years, and
median EDSS at follow-up was 3.0. Multiple lesions were present in 70% on pre-biopsy MRI, and in 83% by last
MRI, with Barkhof criteria fulfilled in 46% prior to biopsy and 55% by follow-up. Only 17% of cases remained
unifocal. Median largest lesion size on T2-weighted images was 4 cm (range 0.5^12), with a discernible size of
2.1cm (range 0.5^7.5). Biopsied lesions demonstrated mass effect in 45% and oedema in 77%. A strong association
was found between lesion size, and presence of mass effect and/or oedema (P _ 0.001). Ring enhancement was
frequent. Most tumefactive features did not correlate with gender, course or diagnosis. Although lesion size
`5 cm was associated with a slightly higher EDSS at last follow-up, long-term prognosis in patients with disease
duration `10 years was better (EDSS 1.5) compared with a population-based multiple sclerosis cohort matched
for disease duration (EDSS 3.5; P _ 0.001). Given the retrospective nature of the study, the precise reason
for biopsy could not always be determined. This study underscores the diagnostically challenging nature
of CNS IDDs that present with atypical clinical or radiographic features. Most have multifocal disease at
onset, and develop RRMS by follow-up. Although increased awareness of this broad spectrum may obviate
need for biopsy in many circumstances, an important role for diagnostic brain biopsy may be required in
some cases.
Keywords: tumefactive multiple sclerosis; demyelinating disease; biopsy; pathology; MRI
Abbreviations: ADEM = acute disseminated encephalomyelitis; CSF = cerebrospinal fluid; CT = computed tomographic;
EDSS = expanded disability status scale; F/U = follow-up; Gd = gadolinium; IDD = inflammatory demyelinating disease;
IQRs = interquartile ranges; MRI = magnetic resonance imaging; OB = oligoclonal bands; OC = Olmsted County;
PVWM = periventricular white matter; T1W = T1-weighted
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Introduction

radiographic features associated with CNS IDD may facilitate
diagnosis, reduce unnecessary surgical or medical interventions and ensure proper long-term management and
treatment.

Methods and Materials
This study, approved by the Mayo Clinic Institutional Review
Board (IRB # 2067–99), is a retrospective review of clinical,
pathological and radiographic material amassed from patients with
biopsy proven CNS IDD identified from an original cohort of 780
CNS IDD biopsy cases belonging to the multiple sclerosis Lesion
Project (MSLP). The MSLP database comprises a unique collection of biopsy-proven CNS IDD cases with detailed pathological,
as well as both retrospective and prospective clinical and radiographic data and forms the basis of an international collaborative
effort to study the pathologic, clinical and radiologic correlates
of the multiple sclerosis lesion (NMSS RG3184-B-3-02). Inclusion
criteria for the current study were: (i) brain biopsy performed as
part of diagnostic evaluation; (ii) pathological evidence of
confluent inflammatory demyelination consistent with multiple
sclerosis, confirmed by a certified neuropathologist (B.W.S., W.B.,
H.L., J.E.P., C.G., F.K.) and (iii) a minimum of 1 MRI available
for review. Specifically excluded were patients with ADEM pathologically defined as demyelination limited to perivenular areas
(n = 14) (Hart and Earle, 1975), as well as Devic’s neuromyelitis
optica defined based on published criteria (n = 4) (Wingerchuk
et al., 1999, 2005). Also excluded were cases of neoplasm, infection, vascular or other non-demyelinating inflammatory CNS
disease, as well as prior history of brain irradiation. A total of
168 patients identified from two medical centres; Mayo Clinic
Rochester, USA (n = 127) and University of Göttingen, Germany
(n = 41), met inclusion criteria.

Clinical material
Clinical information was obtained by certified neurologists (C.F.L.;
I.M.), via medical record review (100%), personal interview and
examination (71%), patient letter or telephone contact (22%) and
family or physician contact (6%). In 140 patients, there was
sufficient clinical documentation obtained via either face-to-face
encounter and neurological examination (n = 119 patients; 90
Mayo; 29 Germany), or telephone interview (n = 21 patients) in
order to establish birth date, gender, date of symptom onset, date
of index attack prompting biopsy, index and other attack symptoms, types and dates of multiple sclerosis treatments administered, estimated EDSS at index attack, date of last follow-up and
EDSS at last follow-up. Clinical course at time of biopsy and at
last follow-up was categorized as first demyelinating event,
monophasic, relapsing–remitting, secondary progressive, primary
progressive or uncertain, when it was unclear if an episode
represented a discrete attack (e.g. seizure). Patients were classified
as having definite or probable multiple sclerosis at last follow-up
by either McDonald or Poser criteria (Poser et al., 1983;
McDonald et al., 2001). Patients with a single neurological episode at last follow-up were classified as an isolated demyelinating
syndrome. Clinical course of multiple sclerosis was based on well
accepted criteria for relapsing–remitting, secondary progressive, or
primary progressive multiple sclerosis (Lublin and Reingold,
1996). When available, pre-biopsy cerebrospinal fluid (CSF)
results were recorded, including white blood cell count/mm3,
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Multiple sclerosis plaques on magnetic resonance imaging
(MRI) generally appear as multiple, well demarcated,
homogenous, small ovoid lesions, lacking mass effect and
often oriented perpendicular to the long axis of the lateral
ventricles (Paty et al., 1988; Barkhof et al., 2003). However,
atypical imaging features have been described, which may
confound the diagnostic process. These include a solitary
large lesion, size 42 cm, associated mass effect, perilesional
oedema and/or the presence of ring enhancement
(Rieth et al., 1981; Sagar et al., 1982; Morimoto et al.,
1985; Hunter et al., 1987; Gutling and Landis, 1989; Paley
et al., 1989; Johnson et al., 1990; Nesbit et al., 1991; Youl
et al., 1991; Giang et al., 1992; Kepes, 1993; Guadagnino et al.,
1994; Maranhao-Fiho et al., 1995; Rusin et al., 1995;
Dagher and Smirniotopoulos, 1996; Kurihara et al., 1996;
Masdeu et al., 1996, 2000; Kumar et al., 1998; Al-Bunyan,
2000; Friedman, 2000; Censori et al., 2001; Khoshyomn
et al., 2002; McAdam et al., 2002; Di Patre et al., 2003;
Iwamoto et al., 2004; Wurm et al., 2004; Schwartz et al.,
2006). Clinical presentations are dependent on lesion
location and size, and as a result are variable and include
headache, cognitive abnormalities, mental confusion,
aphasia, apraxia and/or seizures. These atypical clinical and
imaging presentations may mimic brain tumour, cerebral
abscess or other inflammatory disorders, and may necessitate
a brain biopsy for diagnosis. Histologically, the biopsy may
be misinterpreted as a neoplasm given the hypercellular
nature of these lesions and the frequent presence of
atypical reactive astrocytes (i.e. Creutzfeldt-Peters cells) and
mitotic figures (Zagzag et al., 1993; Annesley-Williams et al.,
2000). A variety of terms including Marburg’s disease,
fulminant multiple sclerosis, acute disseminated encephalomyelitis (ADEM), Balo’s concentric sclerosis, transitional
sclerosis, diffuse myelinoclastic sclerosis, pseudotumoral
multiple sclerosis and tumefactive multiple sclerosis have
been used in the literature when referring to these cases of
CNS inflammatory demyelinating disease (IDD) (Niebler
et al., 1992; Poser et al., 1992; Bolay et al., 1996; Chen et al.,
1996; Dagher and Smirniotopoulos, 1996; Kim et al., 1997;
Ernst et al., 1998; Iniguez et al., 2000; Capello et al., 2001;
Karaarslan et al., 2001; Kotil et al., 2002). As a result,
the literature lacks uniform nomenclature or a clear,
comprehensive description of the clinical and radiographic
spectrum of CNS IDD with tumefactive features. This is due
to the limited number of cases available for study, frequent
lack of pathological confirmation, and/or limited clinical or
radiographic follow-up (Nesbit et al., 1991; Kepes, 1993;
Dagher and Smirniotopoulos, 1996; McAdam et al., 2002;
Hayashi et al., 2003). Published series emphasize the unifocal
and clinically isolated nature of such tumefactive cases
(Kepes, 1993). The purpose of this study is to describe the
clinical and radiographic presentations and outcomes in 168
patients with brain biopsy-confirmed CNS IDD. A better
appreciation of the broad spectrum of clinical and
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total protein (mg/dl), intrathecal synthesis rate (normal or
elevated) and presence or absence of CSF oligoclonal bands
(OB). In addition, visual, brainstem auditory and somatosensory
evoked responses performed prior to biopsy were recorded as
normal or abnormal.
Median EDSS at last follow-up in the biopsied cohort was
compared with a population-based prevalence cohort consisting of
patients with definite (n = 201) and/or probable (n = 14) multiple
sclerosis (using Poser’s criteria), who were residents of Olmsted
County (OC) on December 1, 2000 (none underwent brain
biopsy) (Mayr et al., 2003; Pittock et al., 2004).

Histopathology was available in all 168 cases. A brain biopsy had
been performed at an outside institution in 87% of the cases, and
sent for extramural consultation to a study centre. All biopsies
were performed between September 11, 1987 and August 13, 2005,
with over 1/2 performed since May 6, 2000, likely reflecting the
expanding Mayo and University of Göttingen extramural consultative practices. In all instances, the specimen was reviewed by
at least one board certified neuropathologist. In 20 patients, a
second biopsy was obtained, and in a single patient, a third biopsy
performed. Since the majority of biopsies were performed at other
institutions, tissue material was obtained retrospectively, typically
months to years after the biopsy date, and clinical follow-up was
done by clinicians not originally involved in the care of the patient
at the time of biopsy, it was not possible to determine the precise
indication for brain biopsy in most circumstances.

Radiographic material
A total of 842 brain and 24 spine conventional pre-biopsy and
follow-up MRIs obtained on 168 patients were reviewed. Since
this was a retrospective study, a variety of imaging techniques and
scanners were utilized. However, in the 119 patients who
underwent a face-to-face neurological examination at follow-up,
a standardized contrast enhanced MRI was also performed on a
GE (General Electric Medical Systems, Milwaukee, WI) Signa
1.5T MR scanner using birdcage head coils, a slice thickness of
3 mm and no interslice gap. In all 168 patients, at least one MRI
was reviewed, with at least one pre-biopsy MRI available in 151
patients (90%) and at least one post-biopsy MRI in 148 (88%)
patients. Among those with a pre-biopsy MRI, 95% had a
T1-weighted (T1W), 97% T2W, 69% FLAIR and 95% had a
T1W + gadolinium (Gd) sequence. Among those with a postbiopsy MRI, 98% had a T1W, 100% T2W, 93% FLAIR and 99%
had a T1W + Gd sequence.
Prior to blinded data collection, the radiographic features were
initially defined by consensus among the study investigators (B.E.,
C.F.L., W.B., R.G. and I.M.), with all training sessions occurring
at a single site (Mayo Clinic Rochester). Subsequently, blinded
to the clinical data, a single investigator at each centre evaluated
the MRIs at their respective institutions (R.G., Mayo; I.M.,
Göttingen). Results for all MRI variables identified on 10 randomly selected patients were crossed to assess for agreement,
which was confirmed on all measures of interest. Questions
regarding radiographic interpretations at either study centre were
adjudicated by a certified neuroradiologist (B.E.).
Lesions identified on each brain MRI study were defined as
either the initially biopsied lesion (‘index lesion’), or as other
lesions, enhancing and non-enhancing. These were analysed for a
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variety of radiographic features: location, number, size range
(0.3–2 cm; 2.1–5 cm; 45 cm) of both the T2W margin to margin
signal abnormality and the discernible lesion size when it was
possible to differentiate discrete lesion borders from the surrounding oedema; actual size (cm) of the largest lesion on the scan,
presence and grade of mass effect [mild sulcal effacement, moderate (minimal subfalcine or uncal herniation; 51 cm) or marked
(41 cm subfalcine or uncal herniation)], presence and degree of
oedema [mild (51 mm from the lesion), moderate (1–3 cm from
the lesion) or marked (43 cm from the lesion)], presence of T2W
hypointense rim (defined as a discernible smooth complete thin
border of T2W hypointensity relative to the hyperintensity of both
the lesion centre and surrounding oedema), biopsy defect size
(not detected or tract only; 55 mm; 5 mm–2 cm; 42 cm) and
T1W intensity relative to normal appearing white matter
(isointense, mild/moderate hypointense, severely hypointense,
hyperintense). Enhancement patterns were defined as homogenous
(uniform and solid enhancement throughout the lesion); ring-like
(open-ring when opened toward the gray matter; closed ring when
having a complete circular border and incomplete ring or arc
when only part of the lesion is bordered), or heterogeneous
(variable and complex pattern and distribution of enhancement).
In some patients with a heterogeneous enhancement pattern, more
specific enhancement patterns could be identified and included
the following: diffuse and patchy; ‘fluffy/cotton ball’; nodular
with distinct areas of enhancement each 42 mm amongst nonenhancing areas and punctate enhancement characterized by
distinct areas of enhancement each 52 mm. Complex lesions, or
multiple MRIs performed during a given imaging interval could
result in more than one enhancement pattern.
MRI studies were also evaluated for whether and when
multifocal non-enhancing and enhancing lesions developed, or
whether Barkhof criteria were fulfilled (Barkhof et al., 1997). Spine
MRIs, although included for this analysis, were not analysed for
the various radiographic features detailed above. Visual comparison without registration of the first and last MRI study for a
given patient was also evaluated for the following radiographic
features: overall change in T2W and T1W lesion volume
(unchanged, reduced; minimally to moderately increased, markedly increased); extent of confluent periventricular white matter
(PVWM) disease (none, mild, moderate, severe); presence of
atrophy (none, focal, minimal global, moderate global, severe
global) and overall change in PVWM disease and atrophy
(unchanged, improved or minimally, moderately or markedly
increased). In order to determine if patients with at least one
lesion 42 cm on pre-biopsy MRI had a tendency to relapse with
additional large uni- or multi-focal lesions, we performed a
subgroup analysis of the tumefactive radiographic course in this
cohort.

Statistical analysis
Clinical data were recorded on case report forms and double-data
entered to create SAS version 9 data sets (SAS Institute, Cary, NC,
USA). Radiographic data were entered into a Microsoft Excel
spreadsheet shared between both study sites. All data were subjected to extensive internal consistency checks. Statistical analyses
describing clinical data and comparing clinical outcomes to radiographic features were restricted to the 140 patients with detailed
clinical data, whereas statistical analyses describing radiographic
features included all 168 patients in the cohort in order to increase

Downloaded from https://academic.oup.com/brain/article/131/7/1759/385558 by guest on 17 March 2022

Pathological material

Brain (2008), 131, 1759^1775

1762

Brain (2008), 131, 1759^1775

C. F. Lucchinetti et al.
Table 1 Clinical features of cohort

statistical power and ensure a complete representation of the
radiographic spectrum. Given the variability in the number of
scans among patients, the unit of analysis was based on individual
patients rather than scans, thereby maintaining statistical independence among observations and giving equal weight to each
patient. Imaging data from multiple studies per patient were
collapsed into a single observation per patient as follows: (i) a
patient’s studies were first classified into time periods (pre-biopsy,
concomitant with biopsy and post-biopsy interval); (ii) for
patients with 41 biopsy, the biopsy of interest was considered
to be the last biopsy; (iii) if a patient had 41 study in a given
period, no data reduction was necessary and (iv) if a person had
multiple studies in the period, the patient’s values on a particular
radiographic feature were aggregated by recording the maximal
value for ordered variables, such as maximum lesion size observed
in a period, greatest number of enhancing lesions on a single
study within a period or whether a feature was ever present during
the period. Figure 1 shows a schematic of a prototypic patient
timeline and radiographic intervals of interest. Because not all
subjects had an appropriate study available during each interval of
interest, the sample size or denominator depended upon the
variables being analysed.
Radiographic features were described and analysed separately
for biopsied versus non-biopsied lesions. Continuous variables
were analysed using medians, interquartile ranges (IQRs) and
ranges. Associations between dichotomous variables were analysed
using a chi-square test or if counts were small, by Fisher’s exact
test. Two-sample comparisons of continuous measures were
performed using Wilcoxon rank-sum tests. To evaluate associations between two ordinal variables, Spearman rank-order correlation, denoted by rs, was used. When one variable was binary and
the other ordinal, we used Armitage’s trend test. Kaplan-Meier
survival curves were used to determine time to second relapse, and
Cox proportional hazards models were used to determine whether
specific factors were associated with risk of developing a second
multiple sclerosis event. Median EDSS at last follow-up was compared
between the biopsy and the OC multiple sclerosis prevalence cohorts
using a two sample Wilcoxon rank sum test performed separately
among those with a disease duration55, 5–10 and 4 10 years.
Logistic and linear regression models were used to assess the
association and/or confounding effect of clinical and radiographic
variables such as biopsy defect size, gender and steroids.

1.2 :1
37 (8 ^ 69)
7.1 (3.7, 28.6)
3.9 (2.0, 9.0)
61
29
1
2
1
6
24
51
11
1
3
9
70
9
14
7
3.5 (3.0, 4.5)
3.0 (1.5, 4.0)

Note: values in parentheses are either minimum ^ maximum or
lower quartile, upper quartile.
All tests were two sided and a P-value of 0.05 was used to
indicate significant associations between variables. P-values were
not adjusted for multiple comparisons (O’Brien, 1983; Perneger,
1998). However, we do report P-values to several digits so the
reader may perform Bonferroni-type corrections if desired.

Results
Clinical characteristics of the cohort
Table 1 summarizes the cohort in terms of demographics,
clinical course and diagnoses both prior to biopsy and at
last follow-up. Median age at symptom onset was 37 years.
The index attack leading to brain biopsy was the first neurological event in the majority of patients (61%), and eight
(5%) carried an established diagnosis of multiple sclerosis
prior to biopsy.
Index attack symptoms were typically polysymptomatic
and summarized in Fig. 2, with motor (50%), cognitive
(43%), sensory (36%), cerebellar (31%) and brainstem
(24%) symptoms being most common. A spectrum of
cognitive symptoms was observed, including encephalopathy or confusional state (19%), memory dysfunction
(17%), aphasia (17%), apraxia (4%), Gerstmann syndrome
(4%) and stupor/coma (2%). Visual field defects were seen
in 10%, and seizures in 6%. There were no significant
differences in index attack symptoms, including presence
of stupor/coma, encephalopathy or cognitive dysfunction,
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Fig. 1 Prototypical timeline for study participant. The pre-biopsy
MRI interval represents the time between MRI 1 and brain biopsy,
whereas the post-biopsy MRI interval represents the time
between biopsy and last MRI (MRI 6). Although for most patients
the symptoms leading to brain biopsy (index attack) represented
the first neurological event, in some cases, the neurological history
antedated the index attack (attack 1). At the time of the enrolment
visit, 140 patients had a face-to-face neurological history and
examination, and underwent a standardized MRI study (MRI 5).
Total disease duration was from the time of symptom onset
(attack 1) to last follow-up.

Gender F : M
Age at symptom onset (years)
Disease Duration
Symptom onset to biopsy (weeks)
Symptom onset to last F/U (years)
Clinical course prior to biopsy (%)
First neurological event
Relapsing ^ remitting
Secondary progressive
Primary progressive
Progressive-relapsing
Uncertain
Clinical course at last F/U (%)
Monophasic
Relapsing ^ remitting
Secondary progressive
Primary progressive
Progressive-relapsing
Uncertain
Diagnosis at last F/U (%)
Multiple sclerosis
Probable multiple sclerosis
Isolated demyelinating syndrome
Unknown
EDSS
At time of index attack
At last follow-up

Spectrum of inflammatory CNS demyelination

between patients developing multiple sclerosis and those
having an isolated demyelinating syndrome at last
follow-up.
Pre-biopsy CSF results were available on a subset of
patients. Median protein in 58 patients was 40.5 mg/dl (IQR
30.5, 60.0; range 11–383 mg/dl), with a median white blood
cell count/mm3 among 61 patients of 3.0 (IQR 2, 7; range
0–117). In 22 of 62 patients (35%) IgG synthesis rate was
elevated, and 20 of 60 (33%) had CSF OB. Pre-biopsy
visual evoked responses were prolonged in at least one
eye in 13 of 38 (34%) patients; brainstem auditory evoked
responses delayed in 3 of 13 (23%) and 15 of 25 patients
(60%) had abnormal somatosensory evoked potentials.
Most patients developed definite (70%) or probable
multiple sclerosis (9%) by Poser or McDonald criteria after
a median follow-up of 3.9 years (IQR 2.0, 9.0), with only
14% having an isolated demyelinating syndrome at last
follow-up. The latter patients were significantly older at
symptom onset than were those who developed multiple
sclerosis (47 versus 36 years; P50.001). Although some
patients had a monophasic course (24%), a diagnosis of
multiple sclerosis based on McDonald criteria could still be
established. The estimated median EDSS at time of index
attack was 3.5 (IQR 3.0–4.5, range 0–9.5), and EDSS at last
follow-up was 3.0 (IQR 1.5–4.0, range 0.0–9.5). Based on
Kaplan-Meier estimates, the median time to the second
attack was 4.8 years (Fig. 3). At last clinical follow-up,
25% of patients had been treated with at least one
immunosuppressive agent, and 63.5% had received one or
more disease modifying drugs.

1763

Fig. 3 Kaplan-Meier estimates of the probability of remaining
free of a second attack among those whose biopsy was performed
after the first clinical episode (n = 85). Solid line represents
estimated probability, and dotted lines represent 95% CI. The
median time to second clinical episode was 4.8 years. There
were no specific risk factors (clinical or radiographic) identified
which were associated with a greater risk of developing a second
multiple sclerosis attack.

Since patients in the biopsy cohort had a shorter mean
disease duration than the population-based multiple sclerosis cohort (3.9 years versus 19 years), we analysed EDSS
at last follow-up stratified by disease duration (Fig. 4).
The biopsy cohort had a significantly lower median EDSS
compared with the OC multiple sclerosis cohort among
patients with disease duration 410 years (EDSS 1.5 versus
3.5; P50.001), despite a slightly higher EDSS in patients
with 0–5 years (EDSS 3.0 versus 1.5; P = 0.01) and 5–10
years (EDSS 3.0 versus 2.0; P = 0.04).
Although our study lacked detailed cognitive assessment
at the time of last follow-up, based on EDSS evaluation we
observed that 22% of the cohort had a Cerebral Functional
System’s score of 53 at last follow-up, reflecting moderate
to marked decrease in memory.

Pathological characteristics of the cohort
Biopsies in all 168 cases demonstrated characteristic features
of active inflammatory demyelinating disease, including
hypercellularity with myelin loss (Fig. 5A), reactive gliosis
(Fig. 5B), Creutzfeldt cells (Fig. 5C), myelin protein-laden
macrophages (Fig. 5D and E), variable lymphocytic
inflammation and relative axonal preservation (Fig. 5F).
Neoplasia was excluded in every case. The pathological
diagnosis was initially interpreted as a non-demyelinating
aetiology in 31% of cases by the referring pathologist.
Among misdiagnoses (Table 2), a low grade astrocytoma
was the most frequent (39%). Table 2 summarizes the
pathological features in the cohort.
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Fig. 2 Neurologic symptoms at presentation. Cognitive
abnormalities were frequent, and included memory dysfunction,
mental confusion and disorders of attention as well as disorders
of higher cognitive function including aphasia (17%), apraxia (4%)
and agnosia (4%).
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Radiographic characteristics of the cohort
A median number of five MRI studies were reviewed
per patient (IQR 3–6; range 1–18). The median durations between imaging intervals are summarized in
Table 3.

Lesion number

Lesion location
The biopsied lesion location may have involved multiple
anatomic areas (Fig. 8). Frontal and parietal subcortical
regions were most often affected (50 and 42% of patients,
respectively), and a butterfly configuration involving the
corpus callosum was observed in 12% of cases. In cases
with multifocal lesions, non-biopsied sites included predominantly the periventricular (79%), juxtacortical (61%)
or subcortical (54.5%) regions on both pre- and postbiopsy MRI.

Fig. 5 Pathology of an Active Biopsied multiple sclerosis Lesion. Biopsies from all 168 cases demonstrated the characteristic features of
active inflammatory demyelinating disease consisting of hypercellular lesions with myelin loss (A; Luxol-fast blue and periodic acid
Schiff), reactive gliosis (B; haematoxylin ^ eosin), Creutzfeldt cells (C; haematoxylin ^ eosin), lipid-laden macrophages (D and E;
immunocytochemistry for proteolipid protein) and relative axonal preservation (F; Bielschowsky silver impregnation).
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Fig. 4 Comparison of disability (most recent EDSS) between
biopsied cohort and OC multiple sclerosis prevalence cohort
stratified by disease duration. The OC multiple sclerosis prevalence
cohort is denoted by ‘OC’ and the current biopsy cohort is
denoted by ‘Bx’. Boxes extend to cover the middle 50% of the data.
Median EDSS scores are indicated by the horizontal lines within
each box, mean scores by the diamonds. Whiskers extend to
furthest observation within 1.5 IQRs, with outlying points indicated
by individual circles. Although median EDSS at last follow-up was
slightly higher in the biopsy cohort compared with the OC
multiple sclerosis prevalence cohort in patients with disease
duration between 0 and 5 years (3.0 versus 1.5; P = 0.01), and
5^10 years (3.0 versus 2.0; P = 0.04), the EDSS was significantly
lower in the biopsy cohort for 10+ years (1.5 versus 3.5; P50.001).
Note that EDSS at last follow-up was unknown in eight
patients, therefore, the data reflects 132 rather than 140
biopsied patients in whom detailed clinical information was
available for analysis.

Multiple lesions were present in 70% of cases on prebiopsy, and in 83% of cases on post-biopsy MRIs. Prebiopsy MRI spines were available on 24 patients, and 38%
had spinal cord lesions. Barkhof criteria were fulfilled in
46% of the cases during the pre-biopsy imaging interval,
and 55% at last MRI follow-up (Fig. 6). Figure 7 summarizes the number of additional non-biopsied PD/T2,
T1W hypointense and enhancing lesions observed during
the pre- and post-biopsy imaging intervals.
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Table 2 Pathological features of cohort
38 (4 ^74)

Table 3 Radiographic features on pre-biopsy MRI of
biopsied and non-biopsied lesions
Feature

5.0 (2.3, 8.5)
31
39
15
6
9
9
3
18

Note: values in parentheses are either minimum ^ maximum or
lower quartile, upper quartile.

Size, mass effect and oedema
Table 3 summarizes the pre-biopsy MRI characteristics of
biopsied and non-biopsied lesions with respect to size, and
presence and grade of mass effect and oedema. The median
largest lesion size (T2W margin to margin) on pre-biopsy
MRI was 4 cm (IQR 2.5–6.0; range 0.5–12.0 cm). When
possible to exclude perilesional oedema, the largest median
discernible actual lesion size was 2.1 cm (IQR 1.0–3.5; range
0.5–7.5 cm). Typically, biopsied lesions ranged in size
from 2.1 to 5 cm for both T2W margin-to-margin (50%)
and discernible lesion size (44%). In 45% of cases, a
pre-biopsy MRI showed the biopsied lesion was associated with mass effect, which in 36% was moderate to
severe, whereas oedema was present in 77% of cases,
and was moderate to marked in 41%. Excluding the
biopsied lesion, the presence of one or more lesions larger
than 2 cm was found in 35% of the cases on pre-biopsy,
and in 36% of the cases on post-biopsy MRI. Mass effect
and oedema of non-biopsied lesions was usually mild
in degree (Table 3).

Enhancement
Representative examples of the different enhancement patterns are illustrated in Fig. 9. In order to avoid a potential
confounding effect of the brain biopsy on subsequent
enhancement patterns, analysis of biopsied lesion enhancement patterns was restricted to pre-biopsy MRIs, whereas
non-biopsied lesions were characterized on both pre- and
post-biopsy studies. The biopsied lesion enhanced in 123
(95%) of the cases in whom pre-biopsy T1W Gd scans
were available. There was no correlation between lack of
enhancement on pre-biopsy MRI, and the use of steroids or
other immunosuppressive agents within 4 weeks of the
study.
Figure 10 summarizes the spectrum and frequency of
enhancement patterns observed. Ring enhancement, either
closed, open to gray matter or arc-like, was the most frequent pattern in both biopsied (60%) and non-biopsied
lesions (65%) during the pre-biopsy imaging interval. Closed
rings (Fig. 9H) were more common than open rings

Margins
Well-defined
Diffuse
Size: T2^T2 Margins
0.3^2 cm
2.1^5 cm
45 cm
Largest size (cm)
Size: discernible margins
No discernible margins
0.3^2 cm
2.1^5 cm
45 cm
Largest size (cm)
Mass effect present
Mild
Moderate/marked
Edema present
Mild
Moderate/marked
Duration between MRI intervals
Pre-Biopsy MRI Interval
First MRI to biopsy (weeks)
Closest MRI to biopsy (days)
Post biopsy MRI interval
(years)
First to last MRI interval
(years)
Number of scans/patient

Biopsied (%)

Non-biopsied

73
38

NA
NA

20
NA
50
NA
30
NA
4.0 (IQR 2.5, 6; range 0.5 to 12.0)
26
NA
26
NA
44
NA
4
NA
2.1 (IQR 1, 3.5; range 0.5 to 7.5)
45
22%
64
100%
36
0%
77
69.5%
59
85%
41
15%

1.9 (0.9, 6.8)
5 (1, 10)
2.1 (0.9, 4.3)
2.2 (0.9, 4.4)
5 (3, 6)

Note: unless otherwise indicated, values shown in parentheses are
lower quartile, upper quartile.

(Fig. 9G) or arcs in both biopsied (45.5 versus 22%) and
non-biopsied (52 versus 39%) lesions. On both pre- (54%)
and post-biopsy (45%) MRI, non-biopsied lesions more
often showed a homogenous enhancement pattern.

T2W hypointense rim(s)
Pre-biopsy T2W MRI studies showed a T2W hypointense
complete rim around the biopsied lesion in 45% of cases.
Figure 9I illustrates a classic T2W hypointense rim. T2W
hypointense rims were also associated with non-biopsied
lesions occurring in 30.5% of cases on pre-biopsy and
18.5% on post-biopsy MRI studies. T2W hypointense
rims co-localized with ring enhancement as illustrated in
Fig. 8H and I.

T1W hypointensity
The degree of T1W hypointensity of the biopsied lesion on
pre-biopsy MRI was isointense in 2%, mild to moderately
hypointense in 33% and markedly hypointense in 65% of
cases. Post-biopsy MRI studies revealed biopsy defect sizes
ranging from none/tract only in 6%, 55 mm in 21%,
5 mm–2 cm in 51% and 42 cm in 22%.
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Age at biopsy (years)
Disease duration
Index attack to biopsy (weeks)
Initially misread biopsies (%)
Specific diagnoses (%)
Low grade astrocytoma
High grade astrocytoma
Oligodendroglioma
Infarction
Infection
Lymphoma
Non-diagnostic
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Fig. 8 Biopsy lesion location.

atrophy. The extent of global atrophy between first and
last MRI was unchanged in 63%, minimally or moderately
worse in 29% and markedly worse in 8%.

Correlations between radiographic features

Fig. 7 Number of non-biopsied PD/T2, T1W hypointense and
enhancing lesions on pre- and post-biopsy MRI.

Across all MRI study periods, a strong association was
observed between increasing lesion size and the presence of
mass effect (P50.001), and oedema (P50.001). Only 17%
of cases remained unifocal over the imaging follow-up
period. The unifocal subgroup was more likely to have mass
effect associated with the biopsied lesion on pre-biopsy
scan (61.5 versus 41%; P = 0.028), compared with those
who developed multifocal lesions. A similar relationship
was seen with oedema. Cases that remained unifocal over
the imaging interval tended to have oedema associated with
the biopsied lesion on a pre-biopsy MRI study (93 versus
73%, P = 0.061). No statistically significant association was
observed between lesion size, mass effect or oedema and the
likelihood of fulfilling Barkhof criteria by last follow-up.

Progression of radiographic disease

Relationship between‘Tumefactive’ features
and clinical outcomes

Overall T2 lesion volume from first to last MRI was
reduced in 15%, unchanged in 27% and increased in 58%,
whereas overall T1 lesion volume was reduced in 31%,
unchanged in 31% and increased in 38%. Overall progression in periventricular confluent white matter disease
between first and last MRI was unchanged in 55% and
worsened in 45%. On the first MRI study, there was no
apparent global atrophy in 75%, whereas 14% had minimal
and 11% moderate or severe global atrophy. In contrast, on
last MRI, only half had no apparent global atrophy (50%)
while 23% had minimal and 27% had moderate or severe

We analysed whether there were any correlations between
radiographic features typically associated with neoplasms
(size, mass effect, oedema, ring-enhancement) and specific
demographic or clinical features. There was a statistically
significant, albeit weak correlation, between increasing biopsied lesion size on pre-biopsy MRI and EDSS at follow-up
(rs = 0.25, P = 0.009). Patients with biopsied lesions exceeding 5 cm on pre-biopsy MRI had a higher median EDSS
at follow-up (median EDSS 4.0), compared with patients
with either a 2–5 cm (median EDSS 2.5), or 52 cm (median
EDSS 2.0) biopsied lesion size. However, the weak
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Fig. 6 Percent of patients with multifocality, who fulfilled
Barkhof’s criteria for multiple sclerosis, and who had other
enhancing lesions (among those who were multifocal), pre/
concomitant to biopsy and post-biopsy.
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correlation coefficient suggests little of the variability in
EDSS can be explained by lesion size. A larger biopsied
lesion could prompt a more extensive resection, however,
we found no correlation between the post-biopsy defect size
and EDSS at last follow-up (r = 0.07; P = 0.46). Lesion size
also did not correlate with gender, age at onset or biopsy,
or clinical course and diagnosis prior to biopsy and at
last follow-up. There was no correlation between biopsied
lesion mass effect or oedema on pre-biopsy MRI, and
the subsequent clinical course, diagnosis or EDSS at last

follow-up. Lastly, the enhancement pattern did not correlate
with age, gender, clinical course, diagnosis or EDSS at biopsy
or last-follow-up.
Among the 85 patients whose index attack represented
their first demyelinating event, no specific clinical or radiographic risk factors were associated with a greater risk of
developing a second multiple sclerosis attack. Patients with
an isolated demyelinating syndrome at last follow-up were
as likely to have an MRI demonstrating multiple lesions
(50% of cases) as a solitary lesion (50%). An association
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Fig. 9 Representative examples of different enhancement patterns. (A) homogenous; (B) heterogenous; (C) patchy and diffuse;
(D) cotton-ball; (E) nodular; (F) punctate; (G) open ring; (H) multiple closed rings; (I) multiple T2 hypointense rims co-localize with
ring enhancement (arrows; T2W MRI). (A^H) T1W MRI + Gd.
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between the presence of a greater number of PD/T2 or
T1 hypointense lesions on pre-biopsy MRI (P = 0.005 and
P = 0.005, respectively), and the subsequent development
of multiple sclerosis, however, was noted. Furthermore,
disease progression in terms of overall T2W volume change
between the first and last MRI was greater in the multiple
sclerosis group than in the isolated demyelinating group
(P = 0.002).
Twenty-eight patients had relapses associated with
radiographic evidence of developing at least one or more
lesion(s) 42.0 cm in size. Although these patients had a
slightly higher median EDSS at last follow-up [3.0 (IQR
2.0–4.5)], compared with the remainder of the cohort
[EDSS 2.5 (IQR 1.0–3.5); P = 0.055], no other significant
associations were observed with gender, clinical course or
diagnosis.

Discussion
Clinical presentations
Multiple sclerosis is usually diagnosed by demonstrating
clinical and/or radiographic evidence of dissemination of
disease in time and space (Poser et al., 1983; McDonald
et al., 2001). Although the diagnosis of classic multiple
sclerosis generally does not require surgical intervention,
some cases pose considerable diagnostic difficulty and may
require brain biopsy. The occurrence of large demyelinating
lesions resembling brain tumours are well recognized, and
predominantly described in case reports involving few cases.

The largest previously published clinicopathologic published series of CNS IDD consisted of 31 biopsy proven
cases, but clinical and imaging follow-up in this series was
limited and it was not clear how many patients actually had
an MRI versus a computed tomographic (CT) scan (Kepes,
1993). The current study represents the largest clinicoradiographic series of biopsy-confirmed CNS IDD to
date, and includes both longitudinal clinical and imaging
follow-up.
The occurrence of tumour-like demyelination is reportedly rare, being estimated at 1–2/1000 cases of multiple
sclerosis (Poser et al., 1992). A prevalence of three cases per
million inhabitants per year has been suggested (Paty et al.,
1988). Among 1220 brain biopsies, Hunter et al. observed
only four cases of a demyelinating disease initially suggestive of a brain tumour (Hunter et al., 1987). In
another series, Annesley-Williams et al., reported 14 cases
among 15 394 neuropathological specimens (0.09%)
(Annesley-Williams et al., 2000). Although the true incidence is unknown, these figures are likely an underestimation, given the large number of CNS IDD biopsies
identified via the multiple sclerosis Lesion Project (NMSS
RG3185).
Prior reviews have suggested a female prevalence similar
to that seen in classic forms of multiple sclerosis (Comi,
2004), however, no gender predilection was observed in the
current series. Atypical CNS IDDs can present at any age,
but a median age at onset of 37 years, as reported in the
current study, is consistent with previous reports suggesting
they occur more frequently in the second and third decades
of life (Comi, 2004).
Demyelinating lesions mimicking brain tumours are
thought to be exceedingly rare in the paediatric population.
Of the 19 previously reported cases of tumefactive demyelinating disease in children, only 10 had pathological
confirmation (Hunter et al., 1987; Gutling and Landis,
1989; Giang et al., 1992; Kepes, 1993; Rusin et al., 1995;
Dagher and Smirniotopoulos, 1996; Kumar et al., 1998;
McAdam et al., 2002; Yapici and Eraksoy, 2002). Several
reports suggested that these patients had a comparatively
benign, often monophasic course in comparison to other
forms of demyelinating disease (Kumar et al., 1998; Yapici
and Eraksoy, 2002). In contrast, a more recent series of
four paediatric cases reported that three of four patients
developed RRMS, and one had a monophasic course
(McAdam et al., 2002). Among the seven patients under
age 18 years in our current series, the median age at biopsy
was 11 years (range 4–17 years), and diagnosis at last
follow-up was definite multiple sclerosis (n = 4), probable
multiple sclerosis (n = 1), isolated demyelinating syndrome
(n = 1) and ‘unknown’ (n = 1). To avoid potentially
unnecessary diagnostic interventions, paediatricians, radiologists and neurosurgeons should be aware of the
occurrence of tumefactive demyelinating lesions in the
paediatric population.
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Fig. 10 Frequency of enhancement patterns of biopsied and
non-biopsied lesions. The index (biopsied) lesion enhanced in
123 (95%) of the cases in whom pre-biopsy T1W Gd scans were
available for review. There was no correlation between lack of
enhancement on pre-biopsy MRI, and use of steroids or other
immunosuppressive agents within 4 weeks of the scan of interest.
Non-enhancing biopsied lesions all demonstrated pathological
evidence of active demyelination.
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treatments, it is critical for the neurologist to be aware of
this diagnostic pitfall.
Although the symptoms leading to brain biopsy in our
series represented the first neurological event in most
patients, 8 (5%) already carried an established diagnosis of
multiple sclerosis prior to biopsy. However, a pre-existing
diagnosis of multiple sclerosis does not exclude the
possibility of a coexisting tumour, or additional pathology
(e.g. infection). In 29% of patients, there was a history of
neurological episodes prior to biopsy. In some cases, this
previous history was obtained at the time of last follow-up
(median 3.9 years after biopsy), by a study investigator,
rather than at the time of brain biopsy. These historical
details may have been overlooked by the original physician,
or not reported by the patient at the time of initial
presentation. It is possible that this additional information
may have obviated the need for a brain biopsy in some
cases, particularly if the symptoms were typical of demyelinating disease (e.g. episode of painful loss of vision).
This underscores the importance of obtaining a detailed
neurological history in all such patients, with particular
attention to prior episodes of transient neurological
dysfunction for which the patient may not have sought
medical attention.
The frequency of CSF OB noted prior to brain biopsy is
relatively low (i.e. 33%) in our study cohort. Although
prior studies in acute monosymptomatic demyelinating
syndromes have reported CSF OB positivity ranging from
46% to 75% (Martinelli et al., 1991; Frederiksen et al.,
1992; Rolack et al., 1996; Tumani et al., 1998), the lower
frequency in our study may reflect a selection bias skewed
towards OB negative patients who were more likely to have
undergone brain biopsy in order to secure a diagnosis.
Furthermore, as this was a retrospective study, the quality
of CSF analysis was not uniform and performed in different
laboratories, possibly leading to a higher false negative
rate, particularly if isoelectric focusing was not routinely
performed. Interestingly, several studies have suggested that
the absence of OB at clinical presentation may reflect a
favourable prognostic factor associated with delayed time
to a second event, a benign course, as well as delaying
disability progression during interferon-B treatment
(Stendahl-Brodin and Link, 1980; Sharief and Thompsen,
1991; Paolino et al., 1996; Zeman et al., 1996; Avasarala
et al., 2001; Annunziata et al., 2006). Further studies are
needed in order to determine whether the longer median
interval to second attack and less severe clinical disability
observed in our study is related to CSF OB status.
Among the 36 (29%) patients with a history of prior
neurological episodes, 28 had multifocal lesions on prebiopsy MRI, as well as CSF OB. Although in retrospect
these 28 patients would have likely met Poser or McDonald
criteria based on clinical course, MRI and CSF findings
prior to brain biopsy, it must be emphasized that these
diagnostic criteria are not absolute, since a number of nonmultiple sclerosis diagnoses may also meet Poser and/or
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Included in our series were seven patients with pathologically confirmed CNS IDD older than 65 years, (median
69 years, range 66–74) at the time of brain biopsy. Late
onset of multiple sclerosis is very rare (Ikeda et al., 1992),
with a reported frequency of between 0.6% and 0.75%
of multiple sclerosis cases diagnosed past age 60 years
(Noseworthy et al., 1983; Iwsamoto et al., 2004). An older
age at onset makes distinguishing IDD from tumours such
as malignant glioma, metastasis or lymphoma, even more
challenging. Since primary CNS lymphoma, especially poststeroid therapy, may present with sentinel ‘demyelinating
lesions’ (Alderson et al., 1996), it is important to undertake
post-biopsy surveillance imaging, particularly in the elderly.
Although typical symptoms and signs of multiple
sclerosis include sensory syndromes, haemiplegia, paraplegia
and optic neuritis, the clinical spectrum of CNS IDDs may
be associated with systemic symptoms such as fever, or may
present with focal, multifocal or non-localizing neurological
deficits that mimic tumour or other infectious and/or
inflammatory disorders including abscess, vasculitis or granulomatous disease. Despite a predominance of motor symptoms (mono-, hemi-, paraplegia) in the current series,
a number of less common clinical presentations were
observed. Cognitive dysfunction was a frequent presenting
symptom, and included memory dysfunction, mental
confusion and disorders of attention. These symptoms
may reflect early gray matter cortical involvement. Seizures
reportedly occur in only 1–3% of multiple sclerosis cases
(Nyquist et al., 2002), but were present in nine cases (6%)
in our series. Disorders of higher cognitive function were
also observed. Cortical symptoms including apraxia,
agnosia and aphasia are rare, but have been described
(Kanaha et al., 1971; Olmos-Lau et al., 1977; Roeltgen et al.,
1982; Sagar et al., 1982; Morioka et al., 1996; Comi, 2004).
Although aphasia is reported in only 1% of multiple
sclerosis patients during the course of their disease (Kanaha
et al., 1971), 17% of patients experienced language
disturbances in our series. The posterior visual pathways
are often affected both radiologically and pathologically
in multiple sclerosis, but homonymous visual field defects
are unusual (Hawkins and Behrens, 1975). In one multiple
sclerosis autopsy series (Savitsky and Rangell, 1950),
asymptomatic plaques were found in the optic radiations
in 23 of 50 cases, but no patient had a visual field cut.
In our series, 10% of patients experienced a symptomatic
visual field defect. This likely reflects the selection bias
for larger lesion sizes in our cohort, the result being a
greater impact upon the optic radiations. The presence of
symptoms and signs not typically associated with multiple
sclerosis may cause the clinician to overlook multiple
sclerosis in the differential diagnosis, and increase the
suspicion of neoplasm or infection. An accurate diagnosis
requires knowledge of the broad spectrum of presentations
observed within the family of CNS IDDs. Since misdiagnosis can result in unwarranted procedures and
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McDonald criteria (e.g. primary CNS lymphoma, sarcoidosis, CNS vasculitis, multicentric glioma) (Weinshenker
and Lucchinetti, 1998). Therefore, meeting these multiple
sclerosis diagnostic criteria does not necessarily eliminate
the need for brain biopsy in all circumstances.

Pathological diagnosis

neoplasm tends to bias the pathologists, restricting the
differential diagnosis and promoting diagnostic error.
Biopsy of suspicious lesions are often approached
stereotactically, thus minimizing tissue injury. Nonetheless,
temporary postoperative worsening of neurologic deficits
and even death has been reported. For example, in one
series, a child died after attempted drainage of a presumed
abscess (Rusin et al., 1995). Brain biopsy may also be
associated with persistent neurological deficits related to
surgical trauma. Although we found no association between
the biopsy defect size and EDSS at last follow-up, a number
of patients noted persistence of new postoperative neurological symptoms. Apart from defect size, other biopsy
related factors such as bleeding or trauma in the region of
eloquent anatomy, may contribute to permanent disability
in our cohort.
Since perivenular demyelination was an exclusion
criteria, no cases of ADEM were included in this study.
In-progress studies will compare the clinical and radiographic features of this study cohort with pathologically
confirmed cases of ADEM. In addition, a parallel study
investigates potential associations between specific pathological features on brain biopsy, including the classification
of multiple sclerosis lesions into four subtypes (Lucchinetti
et al., 2000) and specific radiographic features (manuscript
in preparation) (Gavrilova et al., 2007).

Radiographic presentations
Modern MR imaging is the most sensitive method of
detecting the white matter lesions of multiple sclerosis.
T2W MRI displays multiple ovoid lesions, which, within
PVWM and the corpus callosum, are often oriented
perpendicular to the long axis of the ventricular system
(Barkhof et al., 1997; Fazekas et al., 1988, 1999; Miller et al.,
2004). Although MRI has increased our ability to highlight
these lesions, it often fails to provide an unambiguous
diagnosis (Butteriss et al., 2003). This is particularly true
when the lesions present as large, space occupying lesions
misinterpreted as tumour, abscess or infarct. Generally,
multiple sclerosis plaques range from 3 to 16 mm in size.
In the current series, the majority of cases (80%) had T2W
margin-to-margin biopsied lesion sizes 42.0 cm, with a
discernible lesion size 42.0 cm in 48%. The largest T2W
margin-to-margin lesion size was 12.0 cm. Of those with
discernible margins, the largest was 7.5 cm. The largest
previously reported multiple sclerosis plaque measured
7.2 cm, a size determined by CT scan (Hershey et al., 1979).
The definition of ‘tumefactive lesions’ is not consistent in
the literature, and may refer to various combinations of the
following: large size (42 cm), presence of mass effect or
oedema and/or atypical enhancement patterns (ring, heterogenous, etc). Furthermore, some malignancies, such as
metastases and primary CNS lymphoma, may be characterized by multiple small lesions with variable or persistent
enhancement patterns (nodular, punctate, etc). Although the
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Pathological findings common to all our 168 cases included
hypercellular lesions with confluent demyelination, abundant foamy macrophages containing myelin debris, reactive
astrogliosis, ‘relative’ axonal preservation and variable
perivascular and parenchymal lymphocytic inflammation.
Macrophages and astrocytes were commonly closely intermingled. No specific histological features distinguished
specimens derived from patients developing classic multiple
sclerosis from those who had an isolated demyelinating
syndrome.
CNS IDDs, including classic multiple sclerosis, may
pose histopathological challenges. Errors of interpretations
expose patients to inappropriate treatments (Peterson et al.,
1993). In our series, 30% of biopsies were originally misdiagnosed at the referring institution. Astrocytoma, more
often low-grade than high-grade, was the most frequent
misdiagnosis. Since lesions are typically biopsied when
symptomatic, an active enhancing lesion is often targeted.
Histologic features may mimic tumour including hypercellularity, astrocytic pleomorphism, variable nuclear atypia,
a rare mitotic figure and occasional necrosis or cystic
changes (Zagzag et al., 1993; Annesley-Williams et al., 2000;
Sugita et al., 2001). These features, particularly at frozen
section or on small biopsies, pose a potential trap for the
pathologist and are a common cause of litigation. Several
histologic features, however, do point toward a nonneoplastic demyelinating process. These include (i) abundance of foamy macrophages in the absence of coagulative
necrosis, (ii) rather evenly distributed plump, reactive
astrocytes, some with multiple micronuclei (Creutzfeldt
cells), often closely intermingled with macrophages,
(iii) absence of microvascular proliferation, (iv) perivascular
inflammation and (v) relative axonal preservation (Zagzag
et al., 1993; Annesley-Williams et al., 2000; Sugita
et al., 2001).
Distinguishing active demyelination from neoplasm is
critical, since a misdiagnosis can lead to inadvertent
brain irradiation, which apart from the potential risk of
radiation necrosis and post-irradiation neoplasia, is known
to exacerbate underlying inflammatory demyelinating disease (Peterson et al., 1993; Miller et al., 2006). Suboptimal
tissue sampling also represents a major impediment to
accurate histological diagnosis. A good sample should
include perilesional brain tissue and not be entirely subject
to frozen section; smear preparations are preferred.
Diagnostic bias may also be introduced by atypical clinical
or imaging presentations. Imaging suggestive of infection or
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This may also account for the relative infrequency of
posterior fossa (brainstem/cerebellum) and deep gray
matter biopsies in our series. On occasion, IDD spreads
across the corpus callosum in a ‘butterfly’ configuration,
simulating an infiltrative astrocytoma or lymphoma (Rieth
et al., 1981; Hunter et al., 1987; Kalyan-Raman et al., 1987).
This pattern was observed in 10 patients (7%) in our series.
In such instances, there were no differences in patient age,
clinical course prior to biopsy or EDSS at last follow-up
between patients with or without a butterfly lesion. Among
nine with clinical follow-up, eight developed definite multiple sclerosis, and one an isolated demyelinating syndrome
by last follow-up.
A variety of enhancement patterns were observed in this
series. Ring enhancement was the most frequent, both
among biopsied and non-biopsied lesions during the preand post-biopsy imaging intervals. Although a homogenous
enhancement pattern was uncommon among biopsied
lesions, it was often observed in non-biopsied lesions,
both during the pre- and post-imaging interval. In a
retrospective study of 25 patients with definite multiple
sclerosis, 68% showed homogenous enhancement, 23% a
rim pattern and 9% arc-like enhancement (He et al., 2001).
A variety of intracranial pathologies can present as a ring
enhancing lesion on MRI, including glioma, metastasis,
lymphoma, radiation necrosis, infarct, abscess and IDD.
In a recent series, the most prevalent pathologies associated
with ring enhancement were gliomas (40%), metastasis
(30%), abscesses (8%) and multiple sclerosis lesions (6%)
(Schwartz et al., 2006). Although less common in prototypic multiple sclerosis, ring enhancing lesions are more
likely to be biopsied in order to exclude these other
pathologies and may be over-represented in our study.
In the present series, lesions demonstrating ring enhancement, usually had ‘closed rings’. Previous studies have
suggested that the pattern of ring enhancement associated
with demyelination is more often ‘open’, the incomplete
portion abutting cortical gray matter or the basal ganglia
(Masdeu et al., 1996, 2000). Although the ring associated
with abscesses and neoplasms is more often complete
(Haimes et al., 1989), our study underscores the fact that
closed rings may be observed with IDD. Indeed, they
predominated in our series. Heterogenous enhancement
patterns, including punctate and nodular, were common in
both biopsied and non-biopsied lesions in our series.
Although some studies have suggested that tumefactive
demyelinating lesions always enhance (Comi, 2004), we
found that 5% of cases with T1W, Gd enhanced studies
did not, regardless of concomitant steroid use or other
immunosuppressant therapy. Enhancement depends on
many factors, including the time from injection to imaging,
the dosage of the contrast agent, the magnitude of blood
brain barrier abnormalities, the volume of accumulation
and the MR pulse sequence (He et al., 2001). It is important to recognize that the lack of enhancement does not
necessarily exclude a demyelinating pathology.
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minimum of the largest lesion size distribution identified
on pre-biopsy MRI in our study was 0.5 cm, the lower
quartile for the entire cohort was 2.5 cm, while the upper
quartile was 6.0 cm. Among the 168 cases, 13 demonstrated
lesion size on pre-biopsy MRI 52.0 cm. Although not
‘tumefactive’ based strictly on size, 10 of the cases with
lesions 52.0 cm had multiple lesions on pre-biopsy MRI
and a spectrum of enhancement patterns were observed
among 11 with a Gd study, including ring (3); heterogenous (3); diffuse (3); punctate (1) and concentric (1)
patterns. Multiple enhancing lesions were noted in five, and
five cases had associated mild oedema, with mild mass
effect observed in one. Since the majority of our cases
were biopsied elsewhere (87%), and the material was
retrospectively obtained well after the brain biopsy was
performed, it was often not possible to determine the
precise indication for biopsy, particularly among this
subgroup with lesions 52.0 cm. Nonetheless, since all but
13 cases had at least one lesion 42.0 cm, it is probable that
a large lesion size was the primary, but not exclusive factor
contributing to the decision to proceed with brain biopsy.
In comparison with tumours and abscesses, mass effect
and oedema in IDD are said to be proportionally minor
relative to plaque size (Sagar et al., 1982; Gutling and
Landis, 1989; Paley et al., 1989; Nesbit et al., 1991; Giang
et al., 1992; Charil et al., 2006; Omuro et al., 2006). The
largest previously published radiologic series of pathologically confirmed CNS IDD cases (n = 40), included only a
single example with associated mass effect and oedema. The
authors suggested that lack of mass effect differentiates
multiple sclerosis plaques from other space-occupying
lesions (Nesbit et al., 1991). In contrast, our much larger
study found both mass effect and oedema frequently
associated with the biopsied lesion on pre-biopsy MRI.
This also was true of non-biopsied lesions. We also
observed a strong statistical association between increasing
biopsy lesion size and presence of mass effect and oedema
across all MRI study periods. This contradicts prior reports
suggesting that sizable IDD lesions lack mass effect and
oedema. A recent review by the Magnetic Resonance
Network in Multiple Sclerosis (MAGNIMS) defined a
series of ‘MRI red flags’ suggestive of alternative diagnoses
to multiple sclerosis (Charil et al., 2006). It is important to
know that multiple sclerosis and IDDs in general may
present with a broad spectrum of radiological findings, ones
easily mistaken for tumour, abscess or vascular disease.
Some series suggest tumefactive demyelinating lesions
more commonly affect subcortical than PVWM (Kepes,
1993). In our series, the biopsied lesion was most often
supratentorial and subcortical in location, involving the
frontal, parietal, occipital and temporal lobes in decreasing
frequency. In contrast, in the setting of multifocal disease,
non-biopsied lesions were most often situated in the
PVWM. Among multifocal lesions, the one selected for
biopsy is more likely a reflection of surgical bias, rather
than a true indicator of pathologic site predilection.
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Clinical and radiographic disease progression
The long-term evolution of biopsied CNS IDD is not
well defined due to the lack of longitudinal studies with
adequate clinical or radiographic follow-up. In contrast to
prior studies suggesting that acute episodes of tumefactive
IDD are usually isolated and rarely progress to more typical

multiple sclerosis (Kepes, 1993), we found that the majority
(70%) ultimately developed clinically definite multiple
sclerosis, only a very small subset remaining isolated at
last follow-up. Nonetheless, Kaplan-Meier survival estimates
revealed that the median time to the second ‘multiple
sclerosis-defining’ clinical episode was quite long (4.8 years).
This is longer than expected given the conversion rates
observed in untreated non-biopsied patients presenting
with a clinically isolated demyelinating syndrome. In the
CHAMPS study, 50% of placebo patients with a clinically
isolated demyelinating syndrome converted to clinically
definite multiple sclerosis by 3 years (Kepes, 1993; Champs
Study Group, 2001), whereas in the ETOMS study,
45% converted by 2 years (European, 1998). In a large
study of the natural history of multiple sclerosis including
1215 patients, the median time to a second clinical episode
was 1.9 years (Confavreux C, 2002). The reason for the
longer interval to second episode in biopsied patients with
IDD in our cohort is unknown.
Some studies suggest patients with tumefactive multiple
sclerosis have a comparatively benign course compared with
other forms of multiple sclerosis (Kepes, 1993; Hayashi
et al., 2003). We previously reported biopsied multiple
sclerosis patients have a similar clinical course and prognosis compared with a population-based multiple sclerosis
cohort (Pittock et al., 2005). Of the 168 cases in the current
study, 62 (37%) had been reported in our prior series.
Since these are overlapping but not identical populations,
we compared disability (EDSS) at last follow-up in our
study cohort with established disability data from the OC
multiple sclerosis prevalence cohort, stratified for disease
duration. Although we observed that EDSS at last follow-up
was slightly higher in the biopsy cohort compared with the
multiple sclerosis prevalence cohort when matched for
disease durations between 0–5 and 5–10 years, it is well
recognized that EDSS scores in the low range are less
reproducible and a 1 point increase in EDSS when 54 is of
lesser clinical importance than a 1 point rise in EDSS 56.
Interestingly, EDSS in biopsied multiple sclerosis cases
with a disease duration 410 years was significantly less
compared with the prevalence multiple sclerosis cohort
matched for disease duration 410 years, (1.5 versus 3.5
P50.001). These findings suggest that prognosis is not
greatly affected by the appearance of tumefactive lesions,
and the presence of such lesions could potentially protect
against long-term disease progression.
The current study also demonstrates that the radiographic course of biopsied IDD cases resembles what would
be expected in typical multiple sclerosis, with accumulating
T2, T1 and PVWM disease burden as well as progressive
brain atrophy. Prior reports have also emphasized that
large, tumefactive demyelinating lesions tend to remain
radiographically unifocal. In the largest previous clinicopathologic series of 31 patients, only three patients developed additional lesions over the follow-up period (Kepes,
1993). In contrast, we found that only 17% of patients
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Various ring enhancing lesions may have a complete rim
of hypointensity on T2W sequences. Such rims were frequent in our cohort, and co-localized with ring enhancement. T2W hypointense rims are most commonly
associated with abscesses, wherein they are thought to
result from the production of paramagnetic free radicals by
macrophages (Haimes et al., 1989). Hypointense T2W rims,
more often partial than complete, may also occur in
intracranial haematoma, vascular malformations and
tumoural haemorrhage, and correlate with the presence of
haemosiderin-laden macrophages at the lesion’s edge
(Gomori et al., 1985; Atlas et al., 1987). Some have
proposed that in granulomatous disease, T2W rims
correspond to a fibrous rim of granulation and compressed
glial tissues (Gupta et al., 1988). A study by Schwartz et al.
examined the prevalence of T2W hypointense borders in
ring enhancing lesions of various aetiologies (Schwartz
et al., 2006). Abscesses had the highest percentage of
complete hypointense rims, whereas metastases and gliomas
more often featured hypointense arcs and multiple sclerosis
lesions equally showed rims and arcs. Interestingly, nearly
all multiple sclerosis lesions (92%) were centrally homogenous on T2W MRI compared with abscesses in which
56% were centrally homogenous and 44% heterogenous.
Although the presence of a ring enhancing lesion
co-localizing with a complete T2W hypointense rim, and
having a T2W homogenous centre is most likely due to
IDD, given the degree of overlap with other pathologic
processes, these trends do not obviate the need for brain
biopsy in all circumstances.
Prior series of acute IDD subject to biopsy or autopsy
have emphasized their unifocal nature (Nesbit et al., 1991;
Kepes, 1993). In contrast, we observed that the majority of
cases were radiographically multifocal at presentation. Since
these additional lesions were often enhancing, and classic in
their locations, they likely represented true demyelinating
lesions, rather than non-specific white matter abnormalities.
Furthermore, a substantial proportion of patients already
met Barkhof criteria of multiple sclerosis at the time
of presentation. In a series of 31 patients with large
focal cerebral demyelinating lesions (Kepes, 1993), 24 were
reportedly unifocal and seven multifocal on either CT or
MRI. Technical factors may have limited the demonstration
of additional lesions, since many cases were scanned only
by CT, and the assessment of all cases antedated 1991.
Although relatively uncommon in our series, it is still
important to include IDD in the differential diagnosis of a
solitary lesion.
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Indication for brain biopsy
Since the majority (87%) of biopsies were performed
elsewhere, and clinical follow-up was obtained a median of
3.9 years after biopsy by neurologists not originally involved
in the case, the precise reason(s) for biopsy was difficult to
determine retrospectively. Based on the clinical and radiographic features described in our study cohort, reasons for
biopsy most likely included atypical clinical presentations
(e.g. encephalopathy, seizures, aphasia), older age, the presence of at least one large lesion (42.0 cm), associated mass
effect/oedema and/or atypical enhancement patterns. This
study underscores the diagnostically challenging nature
of CNS IDD cases that present with atypical clinical or
radiographic features, and highlights the need for clinicians, radiologists, pathologists and surgeons to recognize
the broad and heterogeneous spectrum of these disorders.
Although a better appreciation of this spectrumsupplemented by a consideration of neurological history,
CSF and evoked potential findings may obviate the need for
brain biopsy in many circumstances, and MR diffusion and
perfusion sequences as well as MRS may help elucidate the
demyelinating nature of the lesions (Ernst et al., 1998;
Metafratzi et al., 2002; Butteriss et al., 2003; Enzinger et al.,
2005), an important role for diagnostic brain biopsy
remains in some cases.

1773

Conclusions
Despite an atypical clinical or radiographic presentation, the
development of multiple sclerosis is the most common
clinical outcome among patients presenting with tumefactive
features. Although it is still not possible to determine
whether a patient presenting with a large tumefactive
cerebral lesion will develop typical multiple sclerosis or
not, our findings suggest the risk is greater than previously
recognized. The majority of patients have a clinical and
radiographic course as well as prognosis similar to prototypic multiple sclerosis. Nonetheless, continued clinical
surveillance is essential given the relatively long duration
between initial clinical presentation and a second event.
Although the pathogenesis of large, focal cerebral demyelinating lesions is still controversial, our study, the largest
clinicopathologic–radiographic series reported to date, does
not support the hypothesis that such lesions occupy an
intermediate position between multiple sclerosis and ADEM,
a hypothesis forwarded by Kepes (1993), represent recurrent
disseminated encephalomyelitis, a theory advocated by
Brinar (2004) or represent a distinct variant of multiple
sclerosis as proposed by Poser et al. (1992). Rather, these
biopsied cases are simply a part of the heterogeneous clinical
and radiographic spectrum of multiple sclerosis.
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